Mizuho raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps an Outperform rating on the shares post the Q3 report. The AVANT Guard trial setback is not linked to a mortality event or initiated by FDA and global Farapulse momentum is sustainable over the medium-term, the analyst tells investors in a research note. The firm believes the pullback in Boston Scientific shares presents a “compelling” entry point.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $100 from $92 at Bernstein
- Boston Scientific price target raised to $98 from $87 at Wells Fargo
- Boston Scientific price target raised to $98 from $92 at Citi
- Boston Scientific (NYSE:BSX) Q3 Earnings Show Significant Sales Growth
- Boston Scientific weakness a buying opportunity, says Stifel